Our results suggest that with respect to genetically predicted HMGCR inhibition and cancer risk, LDL-cholesterol is simply a biomarker of HMGCR inhibition that is accessible, but the true causal pathway is likely via another molecule whose levels are correlated with its LDL-cholesterol lowering effect. This evidence concerns the gene HMGCR and cancer.